The pharmaceutical and healthcare packaging sector has reached a defining moment. Packaging formats such as blister packs, bottles, tubes, pouches, sachets, cartons and protective wraps are indispensable for ensuring sterility, dose accuracy and patient safety. Yet, once used, the overwhelming majority of this packaging follows a linear trajectory towards disposal or destruction.
This linearity now stands in direct conflict with regulatory, environmental and societal expectations. Under the EU Green Deal, pharmaceutical packaging is no longer viewed as an exceptional category insulated from sustainability obligations. Instead, it is increasingly scrutinised as part of the broader packaging waste system – subject to Extended Producer Responsibility (EPR), recycled content expectations, and netzero healthcare ambitions.
Despite this shift, recycling rates remain alarmingly low. Estimates suggest that only around 14% of blister packs – enter any form of dedicated recycling stream. For many other primary and secondary pharmaceutical packaging formats, effective recycling pathways barely exist. Most materials are still incinerated or landfilled, often by regulatory default rather than by design.
The question facing the industry is no longer whether pharmaceutical packaging must become circular, but how this can be achieved without compromising safety, compliance or performance.
Why Pharmaceutical Packaging Has Been Left Behind
Pharmaceutical packaging sits at the intersection of some of the most complex requirements in the packaging world.
This starts with material complexity. Blister packs combine aluminium with multi-layer polymers. Tubes and pouches rely on laminated structures, adhesives and barrier layers. Bottles, closures and dispensers may incorporate pigments, additives and functional components to meet regulatory and performance standards.
Second, there is contamination risk. Packaging that has come into contact with active pharmaceutical ingredients (APIs) cannot be treated in the same way as consumer packaging waste. Conventional mechanical recycling processes are not designed to guarantee the level of decontamination required for highvalue or regulated reuse.
Third, regulatory conservatism plays a role. Once a packaging format has been validated and approved, change is costly and time-consuming. This has historically favoured proven linear materials over innovative circular solutions.
These constraints help explain why pharmaceutical packaging has remained largely outside mainstream recycling systems. However, they do not justify inaction or the lack of development of innovative processes – particularly in light of evolving EU policy.
PPWR and the End of “De Facto Exemptions”
The EU Packaging and Packaging Waste Regulation (PPWR) represents a fundamental shift in how packaging is regulated. Unlike previous directives, PPWR introduces harmonised, binding requirements across Member States, with a strong emphasis on waste reduction, recyclability and recycled content.
Crucially for pharmaceuticals, PPWR signals the end of implicit exemptions based on complexity or safety concerns. While certain medical and pharmaceutical packaging will require exemptions many more could become much more sustainable and the overall direction is clear: most packaging must be designed for circularity, and producers must take responsibility for its end of life.
Under PPWR, claims of “non-recyclability” will increasingly require justification. The burden is shifting from regulators asking whether recycling is possible, to producers demonstrating why it is not.
This regulatory reality demands new thinking – not just about packaging design, but about the new systems that will support collection, sorting, decontamination and recycling.
